Kent E. Kester

8.1k citations

54 papers · 4.7k indexed · 2 hit papers · h-index 34

Public Health, Environmental and Occupational Health top 0.2%
Molecular Biology top 5%
Immunology top 1%
Epidemiology top 5%
Infectious Diseases top 2%

Co-authors: D. Gray Heppner Joe Cohen Urszula Krzych W. Ripley Ballou Christian F. Ockenhouse Gérald Voss Nadia Tornieporth José A. Stoute
Topics: Malaria Research and Control (32 papers)Mosquito-borne diseases and control (21 papers)vaccines and immunoinformatics approaches (19 papers)
Cited by: Virology Public Health, Environmental and Occupational Health Immunology
Journals: New England Journal of Medicine The Lancet Nature Medicine
Partner nations: United States United Kingdom Belgium

In The Last Decade

Kent E. Kester

54 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine againstPlasmodium falciparumMalaria

1997 652 citations José A. Stoute, M. Slaoui et al. New England Journal of Medicine profile →
The promise of mRNA vaccines: a biotech and industrial perspective

2020 325 citations Kent E. Kester et al. profile →

Peers

Countries citing papers authored by Kent E. Kester

Since Specialization

Citations

This map shows the geographic impact of Kent E. Kester's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kent E. Kester with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kent E. Kester more than expected).

Fields of papers citing papers by Kent E. Kester

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kent E. Kester. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kent E. Kester. The network helps show where Kent E. Kester may publish in the future.

Co-authorship network of co-authors of Kent E. Kester

This figure shows the co-authorship network connecting the top 25 collaborators of Kent E. Kester. A scholar is included among the top collaborators of Kent E. Kester based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kent E. Kester. Kent E. Kester is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Characterization of potential biomarkers of reactogenicity of licensed antiviral vaccines: randomized controlled clinical trials conducted by the BIOVACSAFE consortium 2019 ·Scientific Reports ·January Weiner,David Lewis,Jeroen Maertzdorf,Hans‐Joachim Mollenkopf,Caroline L. Bodinham,(unknown),(unknown),(unknown),Alberto Mantovani,Barbara Bottazzi,Philippe Denoël,Geert Leroux‐Roels,Kent E. Kester,Ingileif Jónsdóttir,Robert A. van den Berg,Stefan H. E. Kaufmann,Giuseppe Del Giudice	24
2	Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults 2014 ·Vaccine ·Kent E. Kester,D. Gray Heppner,Philippe Moris,Opokua Ofori‐Anyinam,Urszula Krzych,Nadia Tornieporth,Denise McKinney,Martine Delchambre,Christian F. Ockenhouse,Gérald Voss,Carolyn A. Holland,(unknown),W. Ripley Ballou,Joe Cohen	32
3	Significance of Infectious Agents in Colorectal Cancer Development 2013 ·Journal of Cancer ·Vlado Antonic,Alexander Stojadinovic,Kent E. Kester,Peter J. Weina,Björn L.D.M. Brücher,Mladjan Protić,Itzhak Avital,Mina Izadjoo	59
4	The Relationship between RTS,S Vaccine-Induced Antibodies, CD4+ T Cell Responses and Protection against Plasmodium falciparum Infection 2013 ·PLoS ONE ·Michael White,Philip Bejon,Ally Olotu,Jamie T. Griffin,Eleanor M. Riley,Kent E. Kester,Christian F. Ockenhouse,Azra C. Ghani	122
5	Protective Immunity Induced with the RTS,S/AS Vaccine Is Associated with IL-2 and TNF-α Producing Effector and Central Memory CD4+ T Cells 2011 ·PLoS ONE ·Joanne M. Lumsden,Robert Schwenk,Lisa Rein,Philippe Moris,Michel Janssens,Opokua Ofori‐Anyinam,Joe Cohen,Kent E. Kester,D. Gray Heppner,Urszula Krzych	68
6	Evaluation of RTS,S/AS02A and RTS,S/AS01B in Adults in a High Malaria Transmission Area 2009 ·PLoS ONE ·Mark E. Polhemus,Shon Remich,Bernhards Ogutu,John Waitumbi,Lucas Otieno,(unknown),James F. Cummings,Kent E. Kester,Christian F. Ockenhouse,Ann Stewart,Opokua Ofori‐Anyinam,(unknown),(unknown),Marc Lievens,Marie‐Claude Dubois,Marie‐Ange Demoitié,Amanda Leach,Joe Cohen,W. Ripley Ballou,D. Gray Heppner	94
7	Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-γ and antibody responses in mice 2008 ·Vaccine ·Joseph P. Shott,Shannon McGrath,Maria Grazia Pau,Jerome Custers,Olga Ophorst,Marie‐Ange Demoitié,Marie‐Claude Dubois,Jack Komisar,(unknown),Kent E. Kester,Patrice Dubois,Joe Cohen,Jaap Goudsmit,D. Gray Heppner,V. Ann Stewart	38
8	Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research 2008 ·Vaccine ·Kent E. Kester,James F. Cummings,Christian F. Ockenhouse,Robin Nielsen,(unknown),Daniel M. Gordon,Robert Schwenk,Urszula Krzych,Carolyn A. Holland,(unknown),Megan Dowler,Jackie Williams,Robert A. Wirtz,Nadia Tornieporth,(unknown),Martine Delchambre,Marie‐Ange Demoitié,W. Ripley Ballou,Joe Cohen,D. Gray Heppner	99
9	Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A☆☆☆ 2006 ·Vaccine ·Douglas S. Walsh,Montip Gettayacamin,Wolfgang W. Leitner,Jeffrey A. Lyon,Victoria Stewart,Gérald Marit,Sathit Pichyangkul,Panita Gosi,Pongsri Tongtawe,Kent E. Kester	22
10	Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques 2006 ·Vaccine ·V. Ann Stewart,Douglas S. Walsh,Shannon McGrath,Kent E. Kester,James F. Cummings,Gérald Voss,Martine Delchambre,Nathalie Garçon,Joe Cohen,D. Gray Heppner	28
11	Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine☆ 2005 ·Vaccine ·Christian F. Ockenhouse,Evelina Angov,Kent E. Kester,Carter L. Diggs,Lorraine Soisson,James F. Cummings,Ann Stewart,Dupeh R. Palmer,Babita Mahajan,Urszula Krzych	73
12	Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children 2005 ·Vaccine ·Kalifa Bojang,(unknown),Margaret Pinder,Opokua Ofori‐Anyinam,(unknown),(unknown),Fanta Njie,(unknown),Amanda Leach,Jessica Milman,Regina Rabinovich,Keith P. W. J. McAdam,Kent E. Kester,D. Gray Heppner,Joe Cohen,Nadia Tornieporth,Paul Milligan	64
13	Pre-clinical evaluation of the malaria vaccine candidate . MSP1 formulated with novel adjuvants or with alum 2004 ·Vaccine ·Sathit Pichyangkul,Montip Gettayacamin,Robert F. Miller,Jeffrey A. Lyon,Evelina Angov,Pongsri Tongtawe,David Ruble,(unknown),Kent E. Kester,W. Ripley Ballou	49
14	Protective Immunity Induced with Malaria Vaccine, RTS,S, Is Linked to Plasmodium falciparum Circumsporozoite Protein-Specific CD4+ and CD8+ T Cells Producing IFN-γ 2003 ·The Journal of Immunology ·Peifang Sun,Robert Schwenk,Katherine White,José A. Stoute,Joe Cohen,W. Ripley Ballou,Gérald Voss,Kent E. Kester,D. Gray Heppner,Urszula Krzych	183
15	Pre-Erythrocytic Malaria Vaccines to Prevent <i>Plasmodium falciparum</i> Malaria 2002 ·PubMed ·W. Ripley Ballou,Kent E. Kester,D. Gray Heppner	4
16	Efficacy of Recombinant Circumsporozoite Protein Vaccine Regimens against ExperimentalPlasmodium falciparumMalaria 2001 ·The Journal of Infectious Diseases ·Kent E. Kester,Denise McKinney,Nadia Tornieporth,Christian F. Ockenhouse,D. Gray Heppner,Ted Hall,Urszula Krzych,Martine Delchambre,Gérald Voss,Megan Dowler,(unknown),Janet Wittes,Joe Cohen,W. Ripley Ballou,(unknown)	199
17	New World monkey efficacy trials for malaria vaccine development: critical path or detour? 2001 ·Trends in Parasitology ·D. Gray Heppner,(unknown),Chris Ockenhouse,Kent E. Kester,Jeffrey A. Lyon,Daniel M. Gordon	17
18	A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia. 1999 ·American Journal of Tropical Medicine and Hygiene ·J.F. Doherty,M Pinder,Nadia Tornieporth,(unknown),(unknown),Paul Milligan,W. Ripley Ballou,Carolyn A. Holland,Kent E. Kester,Gérald Voss,P. Momin,Brian Greenwood,Keith P. W. J. McAdam,Joe Cohen	66
19	A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine againstPlasmodium falciparumMalariabreakdown → 1997 ·New England Journal of Medicine ·José A. Stoute,M. Slaoui,D. Gray Heppner,P. Momin,Kent E. Kester,Pierre Desmons,B. T. Wellde,Nathalie Garçon,Urszula Krzych,(unknown),W. Ripley Ballou,Joe Cohen	652
20	Granulomatous Pneumocystis carinii Pneumonia in Patients with Low-Grade Lymphoid Malignancies: A Diagnostic Dilemma 1996 ·Clinical Infectious Diseases ·Kent E. Kester,John C. Byrd,(unknown),(unknown),(unknown),Jeffrey B. Hargis	14

About Kent E. Kester

Kent E. Kester is a scholar working on Virology, Public Health, Environmental and Occupational Health and Parasitology, having authored 54 papers that have together received 4.7k indexed citations. Recurring topics across this work include Malaria Research and Control (32 papers), Mosquito-borne diseases and control (21 papers) and vaccines and immunoinformatics approaches (19 papers). The work is most often cited by research in Virology (635 citations), Public Health, Environmental and Occupational Health (2.8k citations) and Immunology (1.6k citations). Kent E. Kester has collaborated with scholars based in United States, United Kingdom and Belgium. Frequent co-authors include D. Gray Heppner, Joe Cohen, Urszula Krzych, W. Ripley Ballou, Christian F. Ockenhouse, Gérald Voss, Nadia Tornieporth, José A. Stoute, W. Ripley Ballou and Danilo R. Casimiro. Their work appears in journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact